Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Background: Patients following allogeneic keratoplasty are treated with topical and
frequently with systemic steroids to prevent immune reactions. Steroids are known to yield
good results, but exert a wide range of side effects. The efficacy of topial FK506 in
preventing immune reactions has already been demonstrated experimentally. FK506, an
IL-2-inhibitor like Cyclosporin A (CSA), is known to be approximately 100 fold more potent
than CSA. Aim of the study: In this study the efficacy and safety of topical FK506 will be
compared to our standard treatment (i.e. steroids) after penetrating normal-risk
keratoplasty.